trending Market Intelligence /marketintelligence/en/news-insights/trending/cootukzlextx-dxmrub_5a2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sage Therapeutics, Shionogi to collaborate on depressive disorder treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Sage Therapeutics, Shionogi to collaborate on depressive disorder treatment

Sage Therapeutics Inc. and Shionogi & Co. Ltd. entered a collaboration to develop and sell its experimental drug Sage-217 for treating major depressive disorder and other indications.

Under the deal, Osaka, Japan-based Shionogi will shoulder clinical development, regulatory filings and commercialization of Sage-217 in Japan, Taiwan and South Korea.

Shionogi will pay Cambridge, Mass.-based Sage $90 million up front. The latter will also be eligible to receive up to $485 million in milestone payments as well as tiered royalties on sales of Sage-217.

Further, Shionogi granted Sage certain rights to co-promote Sage-217 in Japan in all indications, while Sage maintains the exclusive rights to develop and sell Sage-217 outside of Japan, Taiwan and South Korea.

In February, Sage-217 was granted breakthrough therapy designation by the U.S. Food and Drug Administration based on data from a phase 2 study.